Cerebral Cortical Microvascular Rarefaction in Metabolic Syndrome is Dependent on Insulin Resistance and Loss of Nitric Oxide Bioavailability

Microcirculation

Volumn 22, Issue 6, 2015, Pages 435-445

  Chantler, Paul D ^a   Shrader, Carl D ^a   Tabone, Lawrence E ^a   d'Audiffret, Alexandre C ^a   Huseynova, Khumara ^a   Brooks, Steven D ^a   Branyan, Kayla W ^a   Grogg, Kristin A ^a   Frisbee, Jefferson C ^a  

^a WEST VIRGINIA UNIVERSITY   (United States)

Author keywords

Capillary density; Obesity; Perfusion; Rodent models of cardiovascular disease risk

Indexed keywords

3 NITROTYROSINE; CAPTOPRIL; HYDRALAZINE; METFORMIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; ROSIGLITAZONE; TEMPOL;

ABDOMINAL AORTA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN CORTEX; BRAIN MICROCIRCULATION; CAPILLARY DENSITY; CEREBRAL CORTEX MICROVASCULAR RAREFACTION; CHRONIC DRUG ADMINISTRATION; CONTROLLED STUDY; GLYCEMIC CONTROL; HYPERTENSION; IMMUNOHISTOCHEMISTRY; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MIDDLE CEREBRAL ARTERY; NONHUMAN; PRIORITY JOURNAL; RAT; ANIMAL; BRAIN CIRCULATION; COMPLICATION; DISEASE MODEL; METABOLISM; MICROCIRCULATION; PATHOPHYSIOLOGY; STROKE; VASCULARIZATION; ZUCKER RAT;

RATTUS; RODENTIA;

ANIMALS; CEREBRAL CORTEX; CEREBROVASCULAR CIRCULATION; DISEASE MODELS, ANIMAL; INSULIN RESISTANCE; MALE; METABOLIC SYNDROME X; MICROCIRCULATION; NITRIC OXIDE; RATS; RATS, ZUCKER; STROKE;

EID: 84938880820     PISSN: 10739688     EISSN: 15498719     Source Type: Journal    
DOI: 10.1111/micc.12209     Document Type: Article

References (46)

1. In: Goodman and Gilman's The Pharmacological Basis of Therapeutics, 11th edn, edited by Brunton LL, Lazo JS, Parker KL. York, NY: McGraw-Hill Professional, 2005.
2. Ashoff A, Qadri F, Eggers R, Jöhren O, Raasch W, Dendorfer A. Pioglitazone prevents capillary rarefaction in streptozotocin-diabetic rats independently of glucose control and vascular endothelial growth factor expression. J Vasc Res 49: 260-266, 2012.
3. Bastien M, Poirier P, Lemieux I, Després JP. Overview of epidemiology and contribution of obesity to cardiovascular disease. Prog Cardiovasc Dis 56: 369-381, 2014.
4. Bray GA. The Zucker-fatty rat: a review. Fed Proc 36: 148-153, 1977.
5. Butcher JT, Goodwill AG, Frisbee JC. The ex vivo isolated skeletal microvessel preparation for investigation of vascular reactivity. J Vis Exp 62: pii:3674, 2012.
6. Cipolla MJ, Bishop N, Vinke RS, Godfrey JA. PPAR{gamma} activation prevents hypertensive remodeling of cerebral arteries and improves vascular function in female rats. Stroke 41: 1266-1270, 2010 Jun.
7. de Artiñano Aleixandre A, Miguel Castro M. Experimental rat models to study the metabolic syndrome. Br J Nutr 102: 1246-1253, 2009.
8. Di Minno MN, Tufano A, Ageno W, Prandoni P, Di Minno G. Identifying high-risk individuals for cardiovascular disease: similarities between venous and arterial thrombosis in perspective. A 2011 update. Intern Emerg Med 7: 9-13, 2012.
9. Durand MJ, Moreno C, Greene AS, Lombard JH. Impaired relaxation of cerebral arteries in the absence of elevated salt intake in normotensive congenic rats carrying the Dahl salt-sensitive renin gene. Am J Physiol Heart Circ Physiol 299: H1865-H1874, 2010.
10. Falkner B, Cossrow ND. Prevalence of metabolic syndrome and obesity-associated hypertension in the racial ethnic minorities of the United States. Curr Hypertens Rep 16: 449, 2014.
11. Faure P, Wiernsperger N, Polge C, Favier A, Halimi S. Impairment of the antioxidant properties of serum albumin in patients with diabetes: protective effects of metformin. Clin Sci (Lond) 114: 251-256, 2008.
12. Frisbee JC. Hypertension-independent microvascular rarefaction in the obese Zucker rat model of the metabolic syndrome. Microcirculation 12: 383-392, 2005.
13. Frisbee JC. Reduced nitric oxide bioavailability contributes to skeletal muscle microvessel rarefaction in the metabolic syndrome. Am J Physiol Regul Integr Comp Physiol 289: R307-R316, 2005.
14. Frisbee JC, Delp MD. Vascular function in the metabolic syndrome and the effects on skeletal muscle perfusion: lessons from the obese Zucker rat. Essays Biochem 42: 145-161, 2006.
15. Frisbee JC, Goodwill AG, Frisbee SJ, Butcher JT, Brock RW, Olfert IM, DeVallance ER, Chantler PD. Distinct temporal phases of microvascular rarefaction in skeletal muscle of obese Zucker rats. Am J Physiol Heart Circ Physiol 307: H1714-H1728, 2014.
16. Gealekman O, Brodsky SV, Zhang F, Chander PN, Friedli C, Nasjletti A, Goligorsky MS. Endothelial dysfunction as a modifier of angiogenic response in Zucker diabetic fat rat: amelioration with Ebselen. Kidney Int 66: 2337-2347, 2004.
17. Gealekman O, Burkart A, Chouinard M, Nicoloro SM, Straubhaar J, Corvera S. Enhanced angiogenesis in obesity and in response to PPARgamma activators through adipocyte VEGF and ANGPTL4 production. Am J Physiol Endocrinol Metab 295: E1056-E1064, 2008.
18. Gealekman O, Guseva N, Gurav K, Gusev A, Hartigan C, Thompson M, Malkani S, Corvera S. Effect of rosiglitazone on capillary density and angiogenesis in adipose tissue of normoglycaemic humans in a randomised controlled trial. Diabetologia 55: 2794-2799, 2012.
19. Giannopoulos S, Boden-Albala B, Choi JH, Carrera E, Doyle M, Perez T, Marshall RS. Metabolic syndrome and cerebral vasomotor reactivity. Eur J Neurol 17: 1457-1462, 2010.
20. Group AS, Cushman WC, Evans GW, Byington RP, Goff DC Jr, Grimm RH Jr, Cutler JA, Simons-Morton DG, Basile JN, Corson MA, Probstfield JL, Katz L, Peterson KA, Friedewald WT, Buse JB, Bigger JT, Gerstein HC, Ismail-Beigi F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362: 1575-1585, 2010.
21. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, Gordon DJ, Krauss RM, Savage PJ, Smith SC Jr, Spertus JA, Costa F. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 112: 2735-2752, 2005.
22. Henrich HA, Romen W, Heimgärtner W, Hartung E, Bäumer F. Capillary rarefaction characteristic of the skeletal muscle of hypertensive patients. Klin Wochenschr 66: 54-60, 1988.
23. Koren-Morag N, Goldbourt U, Tanne D. Relation between the metabolic syndrome and ischemic stroke or transient ischemic attack: a prospective cohort study in patients with atherosclerotic cardiovascular disease. Stroke 36: 1366-1371, 2005.
24. Kostapanos MS, Florentin M, Elisaf MS, Mikhailidis DP. Hemostatic factors and the metabolic syndrome. Curr Vasc Pharmacol 11: 880-905, 2013.
25. Levy BI, Ambrosio G, Pries AR, Struijker-Boudier HA. Microcirculation in hypertension: a new target for treatment? Circulation 104: 735-740, 2001.
26. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR, Williams GR. Impact of the metabolic syndrome on mortality from coronary heart disease, cardiovascular disease, and all causes in United States adults. Circulation 110: 1245-1250, 2004.
27. Marshall RS, Rundek T, Sproule DM, Fitzsimmons BF, Schwartz S, Lazar RM. Monitoring of cerebral vasodilatory capacity with transcranial Doppler carbon dioxide inhalation in patients with severe carotid artery disease. Stroke 34: 945-949, 2003.
28. Milton K, Macniven R, Bauman A. Review of the epidemiological evidence for physical activity and health from low- and middle-income countries. Glob Public Health 9: 369-381, 2014.
29. Munzenmaier DH, Greene AS. Chronic angiotensin II AT1 receptor blockade increases cerebral cortical microvessel density. Am J Physiol Heart Circ Physiol 290: H512-H516, 2006.
30. Osmond JM, Mintz JD, Dalton B, Stepp DW. Obesity increases blood pressure, cerebral vascular remodeling, and severity of stroke in the Zucker rat. Hypertension 53: 381-386, 2009.
31. Osmond JM, Mintz JD, Stepp DW. Preventing increased blood pressure in the obese Zucker rat improves severity of stroke. Am J Physiol Heart Circ Physiol 299: H55-H61, 2010.
32. Prakash R, Li W, Qu Z, Johnson MA, Fagan SC, Ergul A. Vascularization pattern after ischemic stroke is different in control versus diabetic rats: relevance to stroke recovery. Stroke 44: 2875-2882, 2013.
33. Prendergast C, Gidding SS. Cardiovascular risk in children and adolescents with type 2 diabetes mellitus. Curr Diab Rep 14: 454, 2014.
34. Raffaitin C, Gin H, Empana JP, Helmer C, Berr C, Tzourio C, Portet F, Dartigues JF, Alperovitch A, Barberger-Gateau P. Metabolic syndrome and risk for incident Alzheimer's disease or vascular dementia: the Three-City Study. Diabetes Care 32: 169-174, 2009.
35. Razay G, Vreugdenhil A, Wilcock G. The metabolic syndrome and Alzheimer disease. Arch Neurol 64: 93-96, 2007.
36. Sardone LD, Renlund R, Willett TL, Fantus IG, Grynpas MD. Effect of rosiglitazone on bone quality in a rat model of insulin resistance and osteoporosis. Diabetes 60: 3271-3278, 2011.
37. Silvestrini M, Vernieri F, Pasqualetti P, Matteis M, Passarelli F, Troisi E, Caltagirone C. Impaired cerebral vasoreactivity and risk of stroke in patients with asymptomatic carotid artery stenosis. JAMA 283: 2122-2127, 2000.
38. Stepp DW, Pollock DM, Frisbee JC. Low-flow vascular remodeling in the metabolic syndrome X. Am J Physiol Heart Circ Physiol 286: H964-H970, 2004.
39. Struyker-Boudier HA, le Noble JL, le Noble FA, Messing MW, van Essen H. Hypertension, the microcirculation and serotonin. Clin Physiol Biochem 8(Suppl 3): 28-39, 1990.
40. Sylvester FA, Stepp DW, Frisbee JC, Lombard JH. High-salt diet depresses acetylcholine reactivity proximal to NOS activation in cerebral arteries. Am J Physiol Heart Circ Physiol 283: H353-H363, 2002.
41. Toblli JE, Cao G, DeRosa G, Di Gennaro F, Forcada P. Angiotensin-converting enzyme inhibition and angiogenesis in myocardium of obese Zucker rats. Am J Hypertens 17: 172-180, 2004.
42. Tofovic SP, Jackson EK. Rat models of the metabolic syndrome. Methods Mol Med 86: 29-46, 2003.
43. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34. Lancet 352: 854-865, 1998.
44. Vanhanen M, Koivisto K, Moilanen L, Helkala EL, Hanninen T, Soininen H, Kervinen K, Kesaniemi YA, Laakso M, Kuusisto J. Association of metabolic syndrome with Alzheimer disease: a population-based study. Neurology 67: 843-847, 2006.
45. Wessels B, Ciapaite J, van den Broek NM, Nicolay K, Prompers JJ. Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner. PLoS ONE 9: e100525, 2014.
46. Wild SH, Byrne CD, Tzoulaki I, Lee AJ, Rumley A, Lowe GD, Fowkes FG. Metabolic syndrome, haemostatic and inflammatory markers, cerebrovascular and peripheral arterial disease: the Edinburgh Artery Study. Atherosclerosis 203: 604-609, 2009.